Cambridge Investment Research Advisors, Inc. Inmune Bio, Inc. Transaction History
Cambridge Investment Research Advisors, Inc.
- $32.9 Billion
- Q2 2025
A detailed history of Cambridge Investment Research Advisors, Inc. transactions in Inmune Bio, Inc. stock. As of the latest transaction made, Cambridge Investment Research Advisors, Inc. holds 32,575 shares of INMB stock, worth $61,241. This represents 0.0% of its overall portfolio holdings.
Number of Shares
32,575
Previous 23,075
41.17%
Holding current value
$61,241
Previous $180,000
58.33%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding INMB
# of Institutions
95Shares Held
6.29MCall Options Held
1.51MPut Options Held
3.34M-
Vanguard Group Inc Valley Forge, PA848KShares$1.59 Million0.0% of portfolio
-
Black Rock Inc. New York, NY813KShares$1.53 Million0.0% of portfolio
-
Cvi Holdings, LLC Wilmington, DE596KShares$1.12 Million45.87% of portfolio
-
Ubs Group Ag449KShares$844,5350.0% of portfolio
-
Geode Capital Management, LLC Boston, MA390KShares$733,0700.0% of portfolio
About Inmune Bio, Inc.
- Ticker INMB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 17,946,000
- Market Cap $33.7M
- Description
- INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on tr...